TEL AVIV, Israel, March 9, 2017 /PRNewswire/ --
Cannabics' Pharmaceutical (CNBX) Board of Directors is proud to announce its addition of several highly-respected professionals to its Board of Advisors. The new Advisors are Dr. Gil Feiler, Dr. Martin Burow, Dr.Tal Mofkadi, Prof. Amos Toren and Dr. Sigalit Ariely-Portnoy.
"We are honored to have the newly appointed members on our team, sharing the research on the therapeutic values of cannabinoids," said Dr. Eyal Ballan, CTO of Cannabics Pharmaceuticals.
The company's Board of Advisors are:
Dr. Gil Feiler - Head of Advisory Board and Business Development Advisor. Dr. Feiler is a banker and hedge fund manager. Dr. Feiler served as Board Member of Advanced Vision Technology, traded on the Frankfurt Stock Exchange (VSJ), served on the Board of Safra Bank Mutual Fund Division; and has served as Administrative advisor for the Government of Ras Al Khaimah, UAE. Dr. Feiler has published extensively on business opportunities and strategies and was a frequent speaker in world events including the World Economic Forum in Davos.
Prof. Amos Toren, MD, Medical Advisor. Prof. Amos Toren is the Director of Pediatric Hemato-Oncology and BMT Department at the Sheba Medical Center since 2001 and a Professor in the division of Hematology, Sackler School of Medicine Tel-Aviv University. Prof. Toren is a specialist in Pediatrics, General Hematology and Pediatric Hemato-Oncology. He also has a PhD degree in genetics and qualified as a Master of Health Administration (MHA) at the Recannati Business School, Tel-Aviv University. Professor Toren runs numerous clinical studies, investigator initiated, company initiated, unicenter as well as multicenter.
Dr. Martin Burow, Scientific Advisor. Dr. Martin Burow is the founder and owner of DMB-Diagnostics GmbH and a specialist at medical sales and marketing activities in Asia and Europe. Dr. Burow specializes in the development and sale of devices for diagnostic analysis and diagnostic markers. Dr. Burow holds a Phd in BioChemistry from the University of Münster.
Dr. Tal Mofkadi, Financial Advisor. Dr. Mofkadi holds a Ph.D in Financial Economics from Tel Aviv University. He is a lecturer at Tel Aviv University, the Interdisciplinary Center in Herzliya and universities abroad. He is the author of 'The Handbook of Corporate Valuation'. Dr. Mofkadi provides expert opinions in financing, economic, and legal proceedings, writing valuations and optimal pricing policies as well as economic analysis of competition and regulatory aspects, risk assessment and more.
Dr. Sigalit Ariely-Portnoy, Strategic Regulatory Advisor, Clinical, Quality and Validation. Dr. Sigalit Ariely-Portnoy has vast experience in the pharmaceutical industry and managed pharmaceutical and chemical plants at Taro pharmaceutical industries Ltd as Operation Group Vice President and in Teva Pharmaceutical Industries Ltd as OSD plant manager. In the last 7 years, Sigalit is the CEO of Gsap, the largest consulting company for pharmaceutical and medical device companies in Israel. Sigalit Ariely-Portnoy has a BSc and PhD in Chemical Engineering and MSc in Bio-Medical Engineering from the Technion - Israel Institute of Technology, Haifa, Israel.
Itamar Borochov, CEO of Cannabics Pharmaceuticals said, "The combination of scientific, financial and regulatory knowledge in our board gives us the tools to make well educated decisions as we continue to evolve further in making our vision relevant and accessible to cancer patients worldwide."
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (CNBX), a U.S-based public company, is dedicated to the development of personalized anti-cancer and palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on January 17th, 2017. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
For further information, please contact:
Cannabics Pharmaceuticals, Inc.
SOURCE Cannabics Pharmaceuticals Inc.